Kamada Ltd.’s (KMDA) human rabies immune globulin therapy KedRAB, proposed as a post-exposure treatment for rabies, is at the FDA altar – with a decision expected on August 29, 2017.KedRAB is being developed by Kamada and Italy-based Kedrion S.p.A. This anti-rabies therapy has been sold in numerous territories outside of the U.S. since 2003 under the brand name KamRAB by Kamada. Currently, in the U.S., GlaxoSmithKline is the only company that is responsible for supplying most of the rabies IgG therapy to the market, and that is RabAvert.KMDA closed Friday's (July 28) trading at $4.50, down 13.04%.